Supernus Pharmaceuticals (SUPN) Downgraded to Hold at ValuEngine

Share on StockTwits

ValuEngine lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a report released on Tuesday morning.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reiterated a buy rating and set a $56.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, September 14th. Zacks Investment Research cut Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, August 1st. Mizuho began coverage on Supernus Pharmaceuticals in a research report on Monday, September 17th. They set a buy rating and a $61.00 price target for the company. Piper Jaffray Companies set a $44.00 price target on Supernus Pharmaceuticals and gave the company a hold rating in a research report on Tuesday, August 28th. Finally, BidaskClub cut Supernus Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, September 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $54.78.

Shares of NASDAQ:SUPN opened at $41.65 on Tuesday. Supernus Pharmaceuticals has a 52-week low of $33.30 and a 52-week high of $61.25. The stock has a market capitalization of $2.43 billion, a PE ratio of 33.06 and a beta of 0.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.10. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm had revenue of $102.99 million during the quarter, compared to analysts’ expectations of $100.75 million. During the same period last year, the business posted $0.29 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts predict that Supernus Pharmaceuticals will post 1.93 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of SUPN. FMR LLC increased its position in shares of Supernus Pharmaceuticals by 1,909.6% in the second quarter. FMR LLC now owns 941,300 shares of the specialty pharmaceutical company’s stock valued at $56,337,000 after buying an additional 894,459 shares in the last quarter. BlackRock Inc. increased its position in shares of Supernus Pharmaceuticals by 8.7% in the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock valued at $460,287,000 after buying an additional 618,722 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 191.3% in the second quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after buying an additional 580,990 shares in the last quarter. Voya Investment Management LLC increased its position in shares of Supernus Pharmaceuticals by 933.5% in the second quarter. Voya Investment Management LLC now owns 585,319 shares of the specialty pharmaceutical company’s stock valued at $35,031,000 after buying an additional 528,685 shares in the last quarter. Finally, Scout Investments Inc. increased its position in shares of Supernus Pharmaceuticals by 233.6% in the second quarter. Scout Investments Inc. now owns 595,096 shares of the specialty pharmaceutical company’s stock valued at $35,617,000 after buying an additional 416,696 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: Compound Interest

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply